Examkin

Question

Difficulty: HardDepressive Disorders

A 42-year-old male marketing executive presents to the clinic for a two-month history of pervasive anhedonia, early morning awakening, and an unintentional 5-kg (11-lb) weight loss. He reports that his symptoms have severely impaired his concentration, leading to a recent formal reprimand at work. He is seeking pharmacologic treatment. Assuming this patient will eventually develop treatment-resistant depression over the next year, arrange the following clinical management steps in the standard chronological sequence according to evidence-based stepped-care guidelines.

  1. 1Screen for a history of manic or hypomanic episodes prior to initiating antidepressant pharmacotherapy.
  2. 2Titrate the initial sertraline dosage to the maximum tolerated therapeutic level to ensure an adequate trial.
  3. 3Augment the optimized sertraline regimen with a second-generation antipsychotic to address a partial response.
  4. 4Cross-taper to an antidepressant of a different pharmacologic class (e.g., venlafaxine) after the augmented regimen fails to achieve remission.
  5. 5Initiate electroconvulsive therapy (ECT) following multiple failed pharmacologic trials and the emergence of severe suicidality.

Answer

The correct chronological sequence for managing this patient's evolving treatment-resistant depression is: screening for bipolar disorder, titrating the initial SSRI to a maximum dose, augmenting with a second agent for partial response, switching to a different class upon augmentation failure, and finally utilizing ECT for severe treatment-resistant symptoms.
The standard stepped-care escalation for major depressive disorder begins with ruling out bipolar disorder to prevent antidepressant-induced mania. Once unipolar depression is confirmed, a first-line agent (e.g., an SSRI) is initiated and titrated to its maximum tolerated dose to ensure an adequate trial. If the patient has a partial response, augmenting with a second agent (like an atypical antipsychotic) is preferred to build on existing progress. If the augmented regimen fails, cross-tapering to a medication in a different class (e.g., an SNRI) is indicated. Finally, if the patient fails multiple adequate trials and develops severe, life-threatening symptoms such as active suicidality, electroconvulsive therapy (ECT) is the definitive next step for treatment-resistant depression.

Step-by-Step Solution

1
Prior to initiating any pharmacotherapy, comprehensively evaluate for bipolar disorder.
A detailed psychiatric history is obtained to rule out past manic or hypomanic episodes.
Antidepressant monotherapy in unrecognized bipolar disorder can induce a manic switch or rapid cycling.
2
Initiate a first-line antidepressant and optimize the dose.
Sertraline is started and titrated to the maximum tolerated therapeutic level over several weeks.
Subtherapeutic dosing is a leading cause of pseudo-resistance; an adequate trial requires maximizing the dose before changing strategies.
3
Implement an augmentation strategy for a partial therapeutic response.
A second-generation antipsychotic (e.g., aripiprazole) is added to the optimized sertraline regimen.
Augmentation is preferred over switching when a patient has a partial response, as it builds upon the partial efficacy already achieved without losing progress.
4
Switch to a different pharmacologic class if the augmented regimen fails.
The patient is cross-tapered from the SSRI to an SNRI (e.g., venlafaxine).
When an optimized and augmented trial fails, switching to an agent with a different mechanism of action (e.g., adding norepinephrine reuptake inhibition) is indicated.
5
Recommend neuromodulation for severe treatment-resistant depression.
Electroconvulsive therapy (ECT) is initiated.
After failing multiple adequate trials of different antidepressant classes, or with the emergence of life-threatening symptoms like severe suicidality, ECT becomes the treatment of choice.

Key Concept

The stepped-care escalation algorithm for major depressive disorder.
Rate this question

Topics

Depressive Disorders

More questions from this topic